Meta-analysis of Clinical Efficacy and Safety of Diammonium Glycyrrhizinate in Treatment of Patients with Drug-induced Liver Injury

OBJECTIVE To system assess the clinical efficacy and safety of diammonium glycyrrhizinate against drug-induced liver injury(DILI). METHODS Studies in Pubmed, EMBase, Cochrane Library, CNKI, Sinomed, Vip and Wanfang database were searched to collect randomized controlled trials(RCTs) regarding the treatment of DILI by diammonium glycyrrhizinate from initial to February 2018. Meta-analysis was conducted by using Rev Man 5.3 statistical software. RESULTS A total of 2 116 patients from 24 RCTs were included. Meta-analysis result showed that compared with control group, diammonium glycyrrhizinate group had higher clinical effective rate, RR=1.20,95% CI(1.12, 1.28), P<0.000 1. And it was superior in reduction of biochemical indicators such as ALT, AST, WMD_(ALT)=-20.01,95% CI(-29.00,-11.02), P<0.000 1; WMD_(AST)=-64.36,95%CI(-92.77,-35.96), P<0.000 1. Also, it was superior in the recovery time for TBIL and AST compared with control group(P<0.05). But there was no statistical significance in reduction of TBIL, ALB, GGT and the rate of drug adverse reaction. CONCLUSION Diammonium glycyrrhizinate is effective in treatment of DILI patients, there is no statistical significance in the rate of drug adverse reaction compared with other protection drugs.